INTRODUCTION {#s1}
============

Cancer is a major public health burden, with an estimate of 14.1 million new cancer cases and 8.2 million cancer-related deaths occurred globally in 2012 \[[@R3]\]. In 2018, 1,735,350 new cancer cases and 609,640 cancer deaths are projected to occur in the United States. It has been reported that over the past decade, the rate of incidence (2005--2014) was nearly linear and without any changes in women, and declined by approximately 2% annually in men, while the rate of cancer death (2006--2015) was declined by about 1.5% annually in both men and women \[[@R32]\]. It is estimated that in 2017, 1,688,780 new cancer cases was diagnosed and 600,920 cancer deaths are estimated to occurred in the United States \[[@R31]\]. Although significant progress has been reached in understanding the mechanism and pathogenesis of different types of cancers, the exact etiology is still not completely understood. Growing evidences indicate that cancer is a multifactorial disease caused by genetic background and environmental interactions \[[@R4], [@R8]\].

Apoptosis, also known as programmed cell death, is involved in physiological cell death \[[@R11]\]. Many factors contribute in the apoptotic pathway, including caspases, pro- and anti-apoptotic Bcl2 family members, and mitochondrial pro-apoptotic proteins \[[@R5], [@R6], [@R22]\]. Defects in the apoptosis machinery may lead to serious disease including cancer, autoimmune disease and drug resistance in tumors \[[@R5], [@R7], [@R26]\].

Programmed cell death protein 6 (*PDCD6*), located on chromosome 5p15.33 contains 43351 bp, is also known as apoptosis-linked gene-2 (*ALG-2*). *PDCD6* gene encodes a 22 kDa calcium-binding protein comprising five serially repetitive EF-hand structures. This protein is one of the prototypic members of the penta-EF-hand protein family. Initially, PDCD6 was considered as a pro-apoptotic protein contributing to T-cell receptor-, Fas-, and glucocorticoid- induced programmed cell death \[[@R30], [@R12]\], as well as endoplasmic reticulum stress induced apoptosis during organ formation \[[@R25], [@R18]\]. In recent years, some PDCD6-interacting proteins have been identified, including Peflin \[[@R14]\], Alix \[[@R21]\], Fas \[[@R12]\] and Annexin XI \[[@R28]\]. However none of them regulates PDCD6 activity, and such factor yet avaits to be identified. Alix and PDCD6 interaction with pro-caspase-8 potentiated cell death induction via tumor necrosis factor receptor 1 (TNFR1) \[[@R19]\]. Several studies have examined the expression of PDCD6 in clinical tumor tissues or cell lines, and found that PDCD6 has opposing effects in different tumors. PDCD6 expression was upregulated in tumor tissue samples from lung, breast, colon cancer, and ovarian cancer, which suggested that PDCD6 might be involved in maintenance of cellular viability \[[@R15], [@R10], [@R17], [@R33], [@R24]\]. In contrast, decreased PDCD6 expression was detected in non-small cell lung cancer (NSCLC), gastric cancer and HeLa cells \[[@R38], [@R40]\].

Recently, it has been shown that that miR-124-3p attenuated tumor metastasis by inhibiting PDCD6 expression, and that the miR-124-3p/PDCD6 signaling axis could potentially be a therapeutic target for patients with advanced breast cancer \[[@R43]\]. Another study showed that the over-expression of miR-124 suppressed PDCD6 expression, inhibited cell proliferation, migration and invasion, and induced apoptosis in SKOV3 and OCVAR3 cells *in vitro* \[[@R41]\]. Furthermorem it has been proposed that miR-183 may function as an oncogene that may increase childhood acute myeloid leukemia (AML) cell proliferation by targeting PDCD6 \[[@R37]\].

Previous studies inspecting the association between *PDCD6* gene polymorphisms and cancer indicated inconclusive and contradictory results \[[@R9], [@R45], [@R44], [@R42]\]. Hence, we have performed a meta-analysis on all the published case-control studies to evaluate the association of *PDCD6* rs3756712 T\>G and rs4957014 T\>G gene polymorphisms with the risk of cancer. Maps of the human *PDCD6* gene with polymorphisms positions is illustrated in Figure [1](#F1){ref-type="fig"}.

![Map of the human *PDCD6* gene with polymorphisms positions indicated\
Exons 1--6 are numbered and represented by black boxes. Both of the rs3756712 T\>G and rs4957014 T\>G variants positioned in intron region.](oncotarget-09-24857-g001){#F1}

METHODOLOGY {#s2}
===========

A comprehensive search in PubMed, Web of Science, Scopus, and Google Scholar databases was performed for all articles describing an association between *PDCD6* polymorphism and cancer risk published up to November 2017 without language restriction. The search strategy was "cancer, carcinoma, tumor, neoplasm", "*PDCD6*, programmed cell death 6", and "polymorphism, mutation, variant". Figure [2](#F2){ref-type="fig"} summarized the process of identifying eligible studies. Relevant studies, eligible for the meta-analysis must meet the following criteria: 1) Original case-control studies of the correlation between the *PDCD6* polymorphism and cancer; 2) studies provided sufficient information of the genotype frequencies of *PDCD6* polymorphism in both cases and controls; 3) the studies have not repeated reports in the same population. The criteria for exclusion were: 1) the articles that describe case reports, reviews, overlapped data, animal or mechanism studies for *PDCD6* polymorphism and cancer; 2) no genotype frequency or genotype information were provided for *PDCD6* polymorphism and cancer; 3) insufficient information for data extraction.

![Flow chart of literature screening and selection in the meta-analysis](oncotarget-09-24857-g002){#F2}

Data extraction {#s2_1}
---------------

Extraction of the data has been conducted by two independent scientists. The data were collected from each study including the first author's name, publication year, ethnicity of participants, the sample size, and the genotype and allele frequencies of cases and controls.

Statistical analysis {#s2_2}
--------------------

Meta-analysis was carried out using Revman 5.3 software, which was provided by the Cochrane Collaboration (Version 5.3. Copenhagen: The Nordic Cochrane Centre, the Cochrane Collaboration, 2014) and STATA 14.1 software (Stata Corporation, College Station, TX, USA). All of the data in the studies are dichotomous data, which has been expressed as odds ratios (ORs) with 95% confidence intervals (CIs) to assess the association between the polymorphisms and cancer. Hardy-Weinberg equilibrium (HWE) for each study was determined by the chi-square tests of control group data. Odds ratios (ORs) and 95% confidence intervals (CIs) were pooled to evaluate the association between the polymorphisms and risk of cancer. For each polymorphism the ORs were calculated for dominant, codominant, recessive, over-dominant, and allele genetic models. Heterogeneity also assessed using the I^2^ statistic, interpreted as the proportion of the total variation contributed by inter-study variation, and the Cochran chi-square *Q*-test, with a significance level of *P* \< 0.10 and *I*^2^ \> 50%. When significant heterogeneity values were returned, the random-effects model (the DerSimonian and Laird method) was used to estimate pooled ORs. Otherwise, the fixed-effects model (the Mantel-Haenszel method) was employed. The significance of the pooled OR was assessed by the *Z*-test, and *P* \< 0.05 was considered to be statistically significant.

Publication bias was evaluated by funnel plot. The degree of asymmetry was measured using Egger's linear regression test; *p* \< 0.05 was considered significant publication bias \[[@R2]\]. The characteristics and relevant data of the included studies are shown in Table [1](#T1){ref-type="table"}. The genotypes of *PDCD6* polymorphisms in controls were all in accordance with HWE (*P* \> 0.05) except for Zhou *et al.* \[[@R45]\] (Table [1](#T1){ref-type="table"}).

###### Distribution information of genotypes and alleles of all studies included in the meta-analysis for rs3756712 T\>G and rs4957014 T\>G polymorphisms of programmed cell death 6 (PDCD6)

  Author      Year   Country   Ethnicity   Cancer type                        Source of control   Genotyping method   Case/control   cases   Controls   HWE                                            
  ----------- ------ --------- ----------- ---------------------------------- ------------------- ------------------- -------------- ------- ---------- ----- ----- ----- ----- ----- ---- ----- ----- -------
  rs3756712                                                                                                                          TT      GT         GG    T     G     TT    GT    GG   T     G     
  Yuan        2017   China     Asian       Endometrial Cancer                 HB                  PCR-RFLP            238/518        153     70         15    376   100   290   184   44   764   272   0.060
  Zhou        2015   China     Asian       Cervical squamous cell carcinoma   HB                  PCR-RFLP            328/541        202     109        17    513   143   298   195   48   791   291   0.053
  Zhou        2014   China     Asian       Bladder cancer                     HB                  PCR-RFLP            332/509        214     101        17    529   135   279   183   47   741   277   0.037
  He          2012   China     Asian       Lung cancer                        HB                  PCR-RFLP            302/306        168     120        14    456   148   168   111   27   447   165   0.167
  rs4957014                                                                                                                          TT      GT         GG    T     G     TT    GT    GG   T     G     
  Yuan        2017   China     Asian       Endometrial Cancer                 HB                  PCR-RFLP            238/518        83      131        24    297   179   234   231   53   699   337   0.720
  Zhou        2015   China     Asian       Cervical squamous cell carcinoma   HB                  PCR-RFLP            328/541        130     142        56    402   254   243   246   52   732   350   0.365
  Zhou        2014   China     Asian       Bladder cancer                     HB                  PCR-RFLP            332/509        170     125        37    465   199   229   232   48   690   328   0.325
  He          2012   China     Asian       Lung cancer                        HB                  PCR-RFLP            302/306        155     124        23    434   170   134   136   36   404   208   0.868

HB, hospital based.

RESULTS {#s3}
=======

Association of PDCD6 rs3756712 T\>G and rs4957014 T\>G polymorphisms and cancer risk {#s3_1}
------------------------------------------------------------------------------------

Four studies \[[@R42], [@R45], [@R44], [@R9]\] reported the association between rs3756712 and rs4957014 polymorphisms and cancer. As shown in Figure [3](#F3){ref-type="fig"} and Table [2](#T2){ref-type="table"}, the results showed that *PDCD6* rs3756712 T\>G polymorphism was significantly associated with decreased risk of cancer under codominant (OR = 0.82, 95%CI = 0.70--0.96, *p* = 0.01, TG vs TT; OR = 0.53, 95%CI = 0.39--0.72, *p* \< 0.0001, GG vs TT), dominant (OR = 0.76, 95%CI = 0.66--0.89, *p* = 0.0004, TG+GG vs TT), recessive (OR = 0.57, 95%CI = 0.43--0.78, *p* = 0.0003, GG vs TT+TG), and allele (OR = 0.76, 95%CI = 0.67--0.86, *p*\<0.00001, G vs T) genetic model. Regarding rs4957014 T\>G polymorphism of *PDCD6*, the finding did not support an association between rs4957014 T\>G polymorphism and cancer risk (Figure [4](#F4){ref-type="fig"} and Table [2](#T2){ref-type="table"}).

![Forest plots of the association between cancer risk and the rs3756712 T\>G polymorphism in the overall study population under the following models\
(**A**) TG *vs* TT, (**B**) GG *vs* TT, (**C**) TG+GG *vs* TT, (**D**) GG *vs* TT+TG, (**E**) TG *vs* TT+GG, and (**F**) G *vs* T.](oncotarget-09-24857-g003){#F3}

###### Meta-analysis of the association between PDCD6 rs3756712 T\>G and rs4957014 T\>G polymorphisms and cancer risk

  SNP         Genetic model   OR     95%CI        *p*         Heterogenecity I^2^ (%)   Egger's test *P*   Begg's test *P*
  ----------- --------------- ------ ------------ ----------- ------------------------- ------------------ -----------------
  rs3756712                                                                                                
              TG vs TT        0.82   0.70--0.96   0.01        23                        0.656              1.00
              GG vs TT        0.53   0.39--0.72   \<0.0001    0                         0.759              1.00
              TG+GG vs TT     0.76   0.66--0.89   0.0004      7                         0.477              0.497
              GG vs TT+TG     0.57   0.43--0.78   0.0003      0                         0.877              0.497
              TG vs TT+GG     0.88   0.75--1.02   0.09        28                        0.729              0.497
              G vs T          0.76   0.67--0.86   \<0.00001   0                         0.448              1.00
  rs4957014                                                                                                
              TG vs TT        0.99   0.70--1.40   0.97        79                        0.661              0.497
              GG vs TT        1.12   0.67--1.89   0.66        77                        0.190              0.174
              TG+GG vs TT     1.02   0.73--1.44   0.90        81                        0.865              0.497
              GG vs TT+TG     1.12   0.70--1.78   0.64        74                        0.018              0.042
              TG vs TT+GG     0.96   0.71--1.31   0.82        77                        0.570              1.00
              G vs T          1.04   0.80--1.34   0.79        81                        0.373              0.174

![Forest plots of the association between cancer risk and the rs4957014 T\>G polymorphism in the overall study population under the following models\
(**A**) TG *vs* TT, (**B**) GG *vs* TT, (**C**) TG+GG *vs* TT, (**D**) GG *vs*TT+TG, (**E**) TG *vs* TT+GG, and (**F**) G *vs* T.](oncotarget-09-24857-g004){#F4}

Heterogeneity and publication bias {#s3_2}
----------------------------------

Heterogeneity of the included studies concerning each polymorphism is shown in Table [2](#T2){ref-type="table"}. A funnel plot was generated as a visual aid to detect risk of publication bias (Figures [5](#F5){ref-type="fig"} and [6](#F6){ref-type="fig"}). Regarding rs3756712 variant, Egger's linear regression analysis suggested no publication bias for this meta-analysis of the codominant, dominant, recessive, overdominanat and allele model (all *P*-values for bias \> 0.05). For rs4957014 polymorphism, the findings indicated that the publication bias exist only for recessive model (Table [2](#T2){ref-type="table"}).

![Funnel plots of the association between cancer risk and the rs3756712 T\>G polymorphism in the overall study population under the following models\
(**A**) TG *vs* TT, (**B**) GG *vs* TT, (**C**) TG+GG *vs* TT, (**D**) GG *vs* TT+TG, (**E**) TG *vs* TT+GG, and (**F**) G *vs* T.](oncotarget-09-24857-g005){#F5}

![Funnel plots of the association between cancer risk and the rs4957014 T\>G polymorphism in the overall study population under the following models\
(**A**) TG *vs* TT, (**B**) GG *vs* TT, (**C**) TG+GG *vs* TT, (**D**) GG *vs* TT+TG, (**E**) TG *vs* TT+GG, and (**F**) G *vs* T.](oncotarget-09-24857-g006){#F6}

Sensitivity analysis {#s3_3}
--------------------

Sensitivity analysis was done using the method of eliminating studies one by one to verify whether our results were influenced by each included study. For rs3756712 variant, the pooled ORs were not considerably altered except in codominant heterozygous model (TG vs TT) and overdominant (TG vs TT+GG) model (Figure [7](#F7){ref-type="fig"}). Regarding rs4957014 variant, the pooled ORs altered only in overdominant model (Figure [8](#F8){ref-type="fig"}). Therefore, the results confirmed that the present meta-analysis was relatively stable and reliable.

![Sensitivity analyses for studies on *PDCD6* rs3756712 T\>G using different genetic models\
(**A**) TG vs TT, (**B**) GG vs TT, (**C**) TG+GG vs TT, (**D**) GG vs TT+TG, (**E**) TG vs TT+GG, and (**F**) G vs T.](oncotarget-09-24857-g007){#F7}

![Sensitivity analyses for studies on *PDCD6* rs4957014 T\>G using different genetic models\
(**A**) TG vs TT, (**B**) GG vs TT, (**C**) TG+GG vs TT, (**D**) GG vs TT+TG, (**E**) TG vs TT+GG, and (**F**) G vs T.](oncotarget-09-24857-g008){#F8}

DISCUSSION {#s4}
==========

PDCD6, a proapoptotic protein, is a Ca^2+^ binding protein of the EF-hand type belonging to the subfamily of penta-EF-hand (PEF) protein that is required for the induction of apoptosis by a variety of stimuli \[[@R35], [@R20]\]. Binding of Ca^2+^ to PDCD6 induces a conformational change \[[@R34]\], which enables the interaction with several proteins, including ALG-2-interacting protein X (ALIX) \[[@R36]\], Sec31A \[[@R39], [@R16]\], and annexin A11 \[[@R28], [@R29]\]. Several lines of evidence suggest that interacting partner of PDCD6 is ALIX/AIP1, an adaptor protein, which has been implicated in apoptotic signaling \[[@R23], [@R13]\].

The pathogenesis of carcinogenesis involves environmental factors, molecular signaling pathways, and host genetic factors \[[@R1], [@R6]\]. Since single nucleotide polymorphism (SNP) is the main cause of human genetic variation, the connection between SNPs and individual risk of cancer has drawn considerable attention \[[@R27], [@R8]\]. As we know, limited polymorphisms have been reported about *PDCD6* gene. Several investigations have been done to find the possible association between two tag SNPs of *PDCD6*, rs3756712 and rs4957014 polymorphisms, and various cancer risk \[[@R45], [@R9], [@R44], [@R42]\]. Zhou *et al.* \[[@R45]\] reported that rs3756712 and rs4957014 polymorphisms of *PDCD6* significantly decreased the risk of bladder cancer. He *et al.* \[[@R9]\] have found no significant association between *PDCD6* rs3756712 variant and risk of Non-small cell lung cancer (NSCLC). Their findings proposed that rs4957014 variant of *PDCD6* significantly decreased the risk of NSCLC. On the other hand, it has been revealed that rs3756712 and rs4957014 polymorphisms of *PDCD6* significantly increased the risk of cervical squamous cell carcinoma (CSCC) \[[@R44]\]. Recently, Yuan *et al.* \[[@R42]\] investigated the association between rs3756712 and rs4957014 polymorphisms of *PDCD6* and risk of CSCC. Their findings suggested that both of the variants significantly increased the risk of CSCC.

Due to contrasting findings about *PDCD6* polymorphism in certain types of cancers, the present meta-analysis was performed to evaluate the impact of two SNPs of *PDCD6* on cancer risk. To our knowledge, this is the first meta-analysis evaluating the impact of *PDCD6* polymorphisms on cancer. The attained results suggest that the *PDCD6* rs3756712 T\>G polymorphism significantly decreased the risk of cancer under codominant, dominant, recessive, and allele genetic model. The findings did not support an association between rs4957014 T\>G polymorphism of *PDCD6* and cancer risk.

In conclusion, to our knowledge, this fist the present study suggested that there is an association between the *PDCD6* rs3756712 T\>G polymorphism and cancer. The rs3756712 T\>G variant may be a potential marker for cancer. Further well-designed case-control studies with a larger sample size and different ethnicities should be done to confirm the findings.
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